Log In
BCIQ
Print this Print this
 

JNJ-61186372

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionBispecific antibody that targets epidermal growth factor receptor (EGFR) and c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)
Molecular Target Epidermal growth factor receptor (EGFR) ; c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat advanced non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerGenmab A/S

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today